Skip to main content

Table 5 Predictors of QoL in stepwise multivariable linear regression analyses

From: Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry

  EQ-5D VAS WHO-5 SGRQ UCSD
Beta 95% CI p value Beta 95% CI p value Beta 95% CI p value Beta 95% CI p value
Age    0.28 0.05; 0.52 0.018  
Disease duration in months    0.07 0.02; 0.12 0.010  
GAP index
 Stage I (ref)    
 Stage II −5.02 −10.78; 0.74 0.087    
 Stage III −12.24 −19.71; −4.78 0.001    
Physician’s overall judgment
 Stable disease (ref) (ref) (ref)  
 Slow progression −5.46 −12.48; 1.55 0.126 −0.42 −1.61; 0.76 0.484 2.59 −3.36; 8.54 0.392  
 Rapid progression −15.28 −25.42; −5.14 0.003 −2.74 −4.73; −0.75 0.007 9.06 1.35; 16.76 0.021  
 No judgement possible −5.43 −12.72; 1.86 0.144 −0.43 −1.68; 0.81 0.495 2.40 −3.98; 8.77 0.460  
Long-term oxygen therapy −14.31 −20.66; −7.95 <0.001 −3.20 −4.32; −2.08 <0.001 7.42 1.74; 13.10 0.011 22.99 13.50; 32.48 <0.001
NYHA functional class
 I (ref)   (ref) (ref)
 II −8.52 −15.67; −1.37 0.020   12.85 5.76; 19.94 <0.001 15.78 7.55; 24.01 <0.001
 III −7.40 −15.36; 0.55 0.068   21.05 13.06; 29.04 <0.001 28.96 18.96; 38.95 <0.001
 IV −24.87 −37.41; −12.32 <0.001   29.63 19.32; 39.94 <0.001 38.49 22.48; 54.51 <0.001
FVC %pred   0.04 0.01; 0.07 0.006 −0.21 −0.36; −0.06 0.005 −0.33 −0.57; −0.09 <0.001
  1. Considered variables in stepwise multivariable linear regression analyses: Disease duration, FVC %pred, Long-term oxygen therapy, Age, Physician’s overall judgment, NYHA stage, Duration since first symptoms, GAP index, No. of comorbidities, 6MWD, Sex, Hospitalisation in last 12 months, Pulmonary rehabilitation, CPI